Back to Blog

Omega-3 for Dry Eyes: What the Evidence Shows

February 19, 2026·4 min read

Dry eye disease affects an estimated 16 million Americans and many more worldwide. The condition ranges from mild irritation to genuinely debilitating pain, blurred vision, and impaired daily function. Omega-3 fatty acids have been one of the most commonly recommended supplements for dry eye — but the largest RCT ever conducted on this question threw cold water on the enthusiasm. Here is what the evidence actually shows.

How omega-3 was supposed to help

The biological rationale for omega-3 in dry eye centers on the meibomian glands — oil-secreting glands along the eyelid margins that produce the lipid layer of the tear film. Without adequate meibum, the aqueous layer of tears evaporates rapidly, creating evaporative dry eye, the most common subtype.

Omega-3 fatty acids, particularly EPA and DHA, have well-documented anti-inflammatory effects mediated through competitive inhibition of arachidonic acid metabolism and production of anti-inflammatory resolvins and protectins. Since chronic inflammation is a central driver of meibomian gland dysfunction and ocular surface disease, the logic of supplementation seemed sound.

Earlier positive studies

Multiple smaller trials published in the 2000s and 2010s suggested omega-3 improved dry eye symptoms and signs. A 2013 randomized trial in dry eye patients showed improvement in Schirmer scores (tear production), TBUT (tear break-up time), and symptom questionnaire scores with 1.5–2g EPA+DHA daily over 3–6 months. Several systematic reviews from this era concluded there was a modest but real benefit.

The DREAM trial: a reckoning

The Dry Eye Assessment and Management (DREAM) study, published in the New England Journal of Medicine in 2018, was the definitive test of omega-3 for dry eye. It enrolled 535 participants with moderate-to-severe dry eye disease and randomized them to either 3g/day EPA+DHA (as fish oil, 2g EPA + 1g DHA) or olive oil placebo for 12 months.

The result: no significant difference in symptom scores (OSDI), clinical signs, or tear film parameters between the omega-3 and olive oil groups. Both groups improved over the trial period, but the improvements were not attributable to omega-3.

One complicating factor: olive oil itself may have mild anti-inflammatory effects, potentially obscuring a real but modest omega-3 benefit. Critics also noted the omega-3 dose, while high by consumer supplement standards, may not have been sufficient to meaningfully alter the omega-3:omega-6 ratio in participants who ate a typical Western diet.

EPA+DHA versus GLA from evening primrose

Some dry eye research has examined gamma-linolenic acid (GLA) from evening primrose oil or borage oil, another anti-inflammatory fatty acid via a different pathway (omega-6 to DGLA rather than arachidonic acid). A few smaller studies suggested GLA combined with EPA+DHA performs better than either alone, though this has not been tested in a trial of DREAM's scale.

Dosing considerations for dry eye

If you choose to trial omega-3 for dry eye:

  • Most positive studies used 2–3g EPA+DHA per day, not the 300–600mg found in typical fish oil capsules
  • Triglyceride form omega-3 is better absorbed than ethyl ester form; re-esterified triglycerides absorb best
  • Taking fish oil with a fatty meal improves absorption by approximately 50%
  • Allow 8–12 weeks minimum before evaluating response

Topical omega-3 eye drops

Omega-3 fatty acids formulated as eye drops (rather than oral supplements) are available and represent a mechanistically different approach — delivering lipids directly to the tear film. Limited RCT data show some benefit for tear film stability and symptoms, and avoids the systemic dosing issues of oral supplementation.

Who might still benefit

Despite the DREAM results, omega-3 supplementation may still be reasonable for:

  • Patients who have not tried it and want a low-risk intervention
  • People with systemic inflammatory conditions where omega-3 is beneficial for other reasons
  • Those with documented omega-3 deficiency or very high omega-6 intake

Omega-3 supplementation carries minimal risk at standard doses and may support meibomian gland health even if OSDI symptom scores do not shift significantly.

Combination approaches

Dry eye management typically requires multiple interventions: preservative-free artificial tears, warm compresses for meibomian gland dysfunction, lid hygiene, prescription cyclosporine or lifitegrast for moderate-severe cases, and environmental modifications. Supplements are at best adjunctive.

The bottom line

The DREAM trial was a rigorous RCT that did not find significant benefit from 3g/day omega-3 versus olive oil placebo for dry eye disease, tempering earlier optimism. Omega-3 remains reasonable to try given low risk and possible benefits beyond dry eye, but it should not replace proven interventions.


To evaluate and organize your eye health and supplement routine based on current evidence, Use Optimize free.

Related Articles

Want to optimize your health?

Create your free account and start tracking what matters.

Sign Up Free